长春高新：目前有超40种处于临床阶段或已提交新药临床试验申请（IND）的候选药物

Core Viewpoint - Changchun High-tech (000661) is focusing on enhancing its core competitiveness by concentrating on traditional strengths in endocrine metabolism and women's health, as well as innovative directions related to oncology, respiratory, and immune systems [1] Product Development - The company is steadily advancing the research and development of products with differentiation and global market potential, currently having over 40 candidate drugs in clinical stages or for which new drug clinical trial applications (IND) have been submitted [1]